Larynx Cancer Biomarkers
Over the last 30 years, the occurrence of head and neck cancer in Spain has been increasing, and now accounts for between 5–10% of malignant tumours diagnosed each year.1 In a new study published in the journal Chromatographia, solid-phase microextraction (SPME) with gas chromatography coupled to mass spectrometry (GC–MS) has been performed to identify two potential biomarkers of epidermoid laryngeal cancer, that could be used in non-invasive diagnostic testing.
Photo Credit: Getty Images/Science Photo Library – PIXOLOGICSTUDIO
Over the last 30 years, the occurrence of head and neck cancer in Spain has been increasing, and now accounts for between 5–10% of malignant tumours diagnosed each year.1 In a new study published in the journal Chromatographia, solid-phase microextraction (SPME) with gas chromatography coupled to mass spectrometry (GC–MS) has been performed to identify two potential biomarkers of epidermoid laryngeal cancer, that could be used in non-invasive diagnostic testing.
Adolfo Toledano, an otolaryngologist from the Alcorcón hospital (Madrid, Spain), approached Rafael García from Rey Juan Carlos University (Madrid, Spain) with the idea of applying volatile compound analysis to the exhaled breath of patients as a method of diagnosing head and neck cancers. García told The Column: “Previously, I had been working on the detection of volatile organic compounds (VOCs) for environmental applications, and the chance to detect these organic compounds from the exhaled air of patients suffering epidermoid laryngeal carcinomas, as non-invasive biomarkers to be used in early detection of this pathology, was an outstanding challenge.”
A group of 31 volunteers were recruited for the study: 20 healthy volunteers, and 11 patients diagnosed with cancer of the larynx undergoing treatment at Alcorcón Hospital. Samples were collected from patients exhaling air after an 8 hr fast using gas sampling bags. SPME was performed to concentrate compounds within the exhaled air, before analysis using GC–MS.
The method was able to detect seven potential biomarkers that were at different concentrations between healthy and diagnosed patients. However, only two were considered to be significantly higher in late-stage cancer patients (T3) when compared with healthy or early-stage patients (T1) — ethanol and 2-butanone.
There is a note of caution from García who said: “The importance of the work is quite relative and it is important to be cautious, since the evaluated subjects are not statistically significant enough to extract definitive conclusions, and also because the more significant VOCs were detected in the later stages of the disease. However, the importance of the investigation is the concept, not only for this serious pathology but also from other neck and head prevalent diseases. I am sure that the results are widely improvable, and it will be improved.”– B.D.
Reference
1. R. García, V. Morales, and Sergio Martín, Chromatographia77, 501–509 (2014).
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
